alfuzosin has been researched along with Urination Disorders in 33 studies
alfuzosin: structure given in first source
Urination Disorders: Abnormalities in the process of URINE voiding, including bladder control, frequency of URINATION, as well as the volume and composition of URINE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Our objective was to assess the effect of the selective alpha(1)-blocker alfuzosin on urodynamic parameters and quality of life in female patients with primary bladder neck obstruction (PBNO)." | 9.14 | Effect of alfuzosin on female primary bladder neck obstruction. ( Athanasopoulos, A; Giannitsas, K; Gyftopoulos, K; Perimenis, P, 2009) |
| "This pilot study was undertaken to assess the efficacy and safety of the alpha(1)-blocker alfuzosin 10mg once daily (OD), the PDE-5 inhibitor sildenafil 25mg OD, and the combination of both on lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) and erectile dysfunction (ED)." | 9.12 | Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. ( Gonzalez, RR; Kaplan, SA; Te, AE, 2007) |
| "To assess the efficacy and safety of a new prolonged release formulation of the uroselective alpha(1)-blocker alfuzosin for a once-daily dosing regimen in patients with lower urinary tract symptoms (LUTS) suggestive of symptomatic benign prostatic hyperplasia (BPH)." | 9.09 | Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study Group. ( Jardin, A; Laval, KU; van Cangh, P; van Kerrebroeck, P, 2000) |
| "To assess the efficacy and safety, and determine the optimal dosage, of a once-daily (OD) formulation of the clinically uroselective alpha(1)-blocker, alfuzosin, in patients with lower urinary tract symptoms and symptomatic benign prostatic hyperplasia." | 9.09 | Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial. ( Roehrborn, CG, 2001) |
| "To assess the effect of the age of patients with benign prostatic hyperplasia (BPH) on the clinical uroselectivity of alfuzosin during general medical practice." | 9.09 | The clinical uroselectivity of alfuzosin is not significantly affected by the age of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. ( Alfaro, V; Badiella, LI; Fernández-Hernando, N; Guil, M; Sánchez-Chapado, M, 2000) |
| "This general practitioner-run study assess the security as well as the efficacy and impact on health-related quality of life of a sustained-release (SR) form of alfuzosin in Spanish patients suffering from lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH)." | 9.09 | Safety and efficacy of sustained-release alfuzosin on lower urinary tract symptoms suggestive of benign prostatic hyperplasia in 3,095 Spanish patients evaluated during general practice. ( Alfaro, V; Badiella, L; Fernández-Hernando, N; Guil, M; Sánchez-Chapado, M, 2000) |
| "In order to assess the efficacy and safety of alfuzosin, an alpha-1 blocker, in symptomatic patients with benign prostatic hyperplasia (BPH), 131 patients who had completed a 6-month placebo-controlled trial conducted on parallel groups entered a 12-month open study; 122 patients were treated with alfuzosin for 12 months and 56 patients for 18 months." | 9.07 | Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 12-18 month assessment. BPHALF Group. ( Attali, P; Bensadoun, H; Delauche-Cavallier, MC; Jardin, A, 1993) |
| "Alfuzosin, a selective alpha 1-adrenoceptor antagonist which is effective in the symptomatic treatment of benign prostatic hyperplasia (BPH), was compared with prazosin, another drug commonly used for the same purpose." | 9.07 | Alpha-blocking treatment with alfuzosin in symptomatic benign prostatic hyperplasia: comparative study with prazosin. The PRAZALF Group. ( Blondin, P; Buzelin, JM; Hebert, M, 1993) |
| "To evaluate the efficacy and adverse effects of alfuzosin for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH)." | 8.82 | Alfuzosin for treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia: a systematic review of efficacy and adverse effects. ( MacDonald, R; Wilt, TJ, 2005) |
| "We analyzed the influence of treatment response on the risk of acute urinary retention and benign prostatic hyperplasia related surgery in 5,792 men complaining of lower urinary tract symptoms who were treated for 6 months with the selective alpha1-blocker alfuzosin at 10 mg once daily." | 7.73 | Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms. ( Alcaraz, A; Elhilali, M; Emberton, M; Lukacs, B; Matzkin, H; Vallancien, G, 2006) |
| " The incidence of sexual function adverse events was higher with tamsulosin than with placebo." | 6.71 | Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia. ( Nordling, J, 2005) |
| "A novel slow release formulation of alfuzosin should improve compliance by reducing dosing to one 10 mg tablet per day." | 5.33 | Early symptom improvement of benign prostatic hyperplasia (BPH) treated with once daily alfuzosin. ( Casey, R; Elhilali, M; Kuzmarov, I; Nickel, JC; Saad, F; Valiquette, L, 2005) |
| " We compared the efficacy of alfuzosin 10 mg alone or in combination with sildenafil 50 mg in the treatment of LUTS due to benign prostatic hyperplasia." | 5.16 | Efficacy of alfuzosin and sildenafil combination in male patients with lower urinary tract symptoms. ( Akyüz, M; Güneş, M; Kalkan, S; Karaman, MI; Koca, O; Öztürk, Mİ, 2012) |
| "Our objective was to assess the effect of the selective alpha(1)-blocker alfuzosin on urodynamic parameters and quality of life in female patients with primary bladder neck obstruction (PBNO)." | 5.14 | Effect of alfuzosin on female primary bladder neck obstruction. ( Athanasopoulos, A; Giannitsas, K; Gyftopoulos, K; Perimenis, P, 2009) |
| "This pilot study was undertaken to assess the efficacy and safety of the alpha(1)-blocker alfuzosin 10mg once daily (OD), the PDE-5 inhibitor sildenafil 25mg OD, and the combination of both on lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) and erectile dysfunction (ED)." | 5.12 | Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. ( Gonzalez, RR; Kaplan, SA; Te, AE, 2007) |
| "To assess the efficacy and safety of a new prolonged release formulation of the uroselective alpha(1)-blocker alfuzosin for a once-daily dosing regimen in patients with lower urinary tract symptoms (LUTS) suggestive of symptomatic benign prostatic hyperplasia (BPH)." | 5.09 | Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study Group. ( Jardin, A; Laval, KU; van Cangh, P; van Kerrebroeck, P, 2000) |
| "This general practitioner-run study assess the security as well as the efficacy and impact on health-related quality of life of a sustained-release (SR) form of alfuzosin in Spanish patients suffering from lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH)." | 5.09 | Safety and efficacy of sustained-release alfuzosin on lower urinary tract symptoms suggestive of benign prostatic hyperplasia in 3,095 Spanish patients evaluated during general practice. ( Alfaro, V; Badiella, L; Fernández-Hernando, N; Guil, M; Sánchez-Chapado, M, 2000) |
| "To assess the effect of the age of patients with benign prostatic hyperplasia (BPH) on the clinical uroselectivity of alfuzosin during general medical practice." | 5.09 | The clinical uroselectivity of alfuzosin is not significantly affected by the age of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. ( Alfaro, V; Badiella, LI; Fernández-Hernando, N; Guil, M; Sánchez-Chapado, M, 2000) |
| "To assess the efficacy and safety, and determine the optimal dosage, of a once-daily (OD) formulation of the clinically uroselective alpha(1)-blocker, alfuzosin, in patients with lower urinary tract symptoms and symptomatic benign prostatic hyperplasia." | 5.09 | Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial. ( Roehrborn, CG, 2001) |
| "To assess the symptomatic outcome following transurethral prostatectomy (TURP), alpha-blockade and placebo treatment in uncomplicated benign prostatic hyperplasia (BPH), 260 patients were evaluated with the recently formulated Danish Prostatic Symptom Score (DAN-PSS-1) system: 205 were randomized to either the selective alpha-blocker alfuzosin or placebo and 55 underwent TURP." | 5.08 | Symptomatic outcome of transurethral prostatectomy, alpha-blockade and placebo in the treatment of benign prostatic hyperplasia. Evaluation of treatment with the Danish Prostatic Symptom Score (DAN-PSS-1) system. The ALFECH Study Group. ( Flyger, H; Hansen, BJ; Mensink, HJ; Meyhoff, HH; Mortensen, S, 1996) |
| "In order to assess the efficacy and safety of alfuzosin, an alpha-1 blocker, in symptomatic patients with benign prostatic hyperplasia (BPH), 131 patients who had completed a 6-month placebo-controlled trial conducted on parallel groups entered a 12-month open study; 122 patients were treated with alfuzosin for 12 months and 56 patients for 18 months." | 5.07 | Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 12-18 month assessment. BPHALF Group. ( Attali, P; Bensadoun, H; Delauche-Cavallier, MC; Jardin, A, 1993) |
| "Alfuzosin, a selective alpha 1-adrenoceptor antagonist which is effective in the symptomatic treatment of benign prostatic hyperplasia (BPH), was compared with prazosin, another drug commonly used for the same purpose." | 5.07 | Alpha-blocking treatment with alfuzosin in symptomatic benign prostatic hyperplasia: comparative study with prazosin. The PRAZALF Group. ( Blondin, P; Buzelin, JM; Hebert, M, 1993) |
| "To evaluate the efficacy and adverse effects of alfuzosin for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH)." | 4.82 | Alfuzosin for treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia: a systematic review of efficacy and adverse effects. ( MacDonald, R; Wilt, TJ, 2005) |
| "To assess the predictors of acute urinary retention (AUR) and/or surgery related to benign prostatic hyperplasia (BPH) in 3514 men complaining of lower urinary tract symptoms and treated for 6 months with the selective alpha1-blocker alfuzosin at 10 mg once daily." | 3.73 | Symptom deterioration during treatment and history of AUR are the strongest predictors for AUR and BPH-related surgery in men with LUTS treated with alfuzosin 10 mg once daily. ( Alcaraz, A; Elhilali, M; Emberton, M; Hartung, R; Harving, N; Matzkin, H; Vallancien, G; van Moorselaar, J, 2005) |
| "Alfuzosin (10 mg) OD is effective and well tolerated, and it has marginal effects on blood pressure, including in elderly patients and those with hypertension, ischemic heart disease or diabetes and those receiving antihypertensive agents." | 3.73 | Age, comorbidity and hypertensive co-medication do not affect cardiovascular tolerability of 10 mg alfuzosin once daily. ( Alcaraz, A; Elhilali, M; Emberton, M; Hartung, R; Harving, N; Matzkin, H; Vallancien, G; van Moorselaar, J, 2006) |
| "We analyzed the influence of treatment response on the risk of acute urinary retention and benign prostatic hyperplasia related surgery in 5,792 men complaining of lower urinary tract symptoms who were treated for 6 months with the selective alpha1-blocker alfuzosin at 10 mg once daily." | 3.73 | Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms. ( Alcaraz, A; Elhilali, M; Emberton, M; Lukacs, B; Matzkin, H; Vallancien, G, 2006) |
| "Doxazosin and alfuzosin were both well tolerated." | 2.71 | Comparative efficacy of two alpha-adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement. ( de Reijke, TM; Klarskov, P, 2004) |
| " The incidence of sexual function adverse events was higher with tamsulosin than with placebo." | 2.71 | Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia. ( Nordling, J, 2005) |
| " To date, the role of varying dosing regimens in responding patients has not been well studied." | 2.69 | Intermittent alpha-blocker therapy in the treatment of men with lower urinary tract symptoms. ( Cologna, A; Kaplan, SA; Kohn, IJ; Martins, AC; Reis, RB; Suaid, HJ; Te, AE, 1998) |
| "Alfuzosin was demonstrated to be effective with respect to out-flow obstructive symptoms (quality of the stream, hesitancy, sensation of incomplete emptying of the bladder) and other functional symptoms (diurnal frequency and nocturia)." | 2.66 | [Efficacy of an alpha-blocker, alfuzosin, on urinary disorders in men with prostatic adenoma. Intermediate results of a European multicenter study]. ( Jardin, A, 1988) |
| ") formulation of alfuzosin has recently been developed in order to improve the convenience of dosing and to provide optimal pharmacokinetic coverage over a 24-h period." | 2.41 | Alfuzosin: a clinically uroselective alpha1-blocker. ( Höfner, K; Jonas, U, 2002) |
| "A novel slow release formulation of alfuzosin should improve compliance by reducing dosing to one 10 mg tablet per day." | 1.33 | Early symptom improvement of benign prostatic hyperplasia (BPH) treated with once daily alfuzosin. ( Casey, R; Elhilali, M; Kuzmarov, I; Nickel, JC; Saad, F; Valiquette, L, 2005) |
| "To construct and validate a short-form benign prostatic hypertrophy (BPH) health-related quality-of-life (HRQL) questionnaire which is more practical in use and as informative as the 20-item visual analogue scale questionnaire (QOL20) previously validated in French." | 1.30 | Construction and validation of a short-form benign prostatic hypertrophy health-related quality-of-life questionnaire. BPH Group in General Practice. ( Comet, D; Grange, JC; Lukacs, B; Thibault, P, 1997) |
| "alfuzosin." | 1.28 | Bladder-neck opening test in spinal cord injury patients using a new i.v. alpha-blocking agent, alfuzosin. ( Bérard, E; Cramer, P; Depassio, J; Neveux, E; Régnier, F, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (6.06) | 18.7374 |
| 1990's | 9 (27.27) | 18.2507 |
| 2000's | 20 (60.61) | 29.6817 |
| 2010's | 2 (6.06) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Athanasopoulos, A | 1 |
| Gyftopoulos, K | 1 |
| Giannitsas, K | 1 |
| Perimenis, P | 1 |
| Delgado Alvira, R | 1 |
| Calleja Aguayo, E | 1 |
| Rihuete Heras, MA | 1 |
| Ruiz de Temiño Bravo, M | 1 |
| Gracia Romero, J | 1 |
| Öztürk, Mİ | 1 |
| Kalkan, S | 1 |
| Koca, O | 1 |
| Güneş, M | 1 |
| Akyüz, M | 1 |
| Karaman, MI | 1 |
| Brown, GA | 1 |
| Sussman, DO | 1 |
| de Reijke, TM | 1 |
| Klarskov, P | 1 |
| van Moorselaar, RJ | 1 |
| Hartung, R | 3 |
| Emberton, M | 5 |
| Harving, N | 3 |
| Matzkin, H | 4 |
| Elhilali, M | 5 |
| Alcaraz, A | 4 |
| Vallancien, G | 4 |
| Bozlu, M | 1 |
| Ulusoy, E | 1 |
| Cayan, S | 1 |
| Akbay, E | 2 |
| Görür, S | 1 |
| Nordling, J | 3 |
| van Moorselaar, J | 2 |
| Saad, F | 1 |
| Nickel, JC | 1 |
| Valiquette, L | 1 |
| Casey, R | 1 |
| Kuzmarov, I | 1 |
| Seftel, A | 1 |
| MacDonald, R | 1 |
| Wilt, TJ | 1 |
| Armitage, JN | 1 |
| Lukacs, B | 2 |
| Kaplan, SA | 2 |
| Gonzalez, RR | 1 |
| Te, AE | 2 |
| Sciarra, A | 1 |
| Buzelin, JM | 1 |
| Hebert, M | 1 |
| Blondin, P | 1 |
| Hansen, BJ | 3 |
| Flyger, H | 3 |
| Brasso, K | 1 |
| Schou, J | 1 |
| Thorup Andersen, J | 1 |
| Mortensen, S | 3 |
| Meyhoff, HH | 2 |
| Walter, S | 1 |
| Hald, T | 2 |
| Mensink, HJ | 2 |
| D'Armiento, M | 1 |
| Damiano, R | 1 |
| De Sio, M | 1 |
| Perdonà, S | 1 |
| Santonastaso, C | 1 |
| Mattace Raso, D | 1 |
| Comet, D | 1 |
| Grange, JC | 1 |
| Thibault, P | 1 |
| Riehmann, M | 1 |
| Hendolin, N | 1 |
| Reis, RB | 1 |
| Cologna, A | 1 |
| Suaid, HJ | 1 |
| Martins, AC | 1 |
| Kohn, IJ | 1 |
| Jardin, A | 3 |
| Bensadoun, H | 1 |
| Delauche-Cavallier, MC | 2 |
| Attali, P | 2 |
| van Kerrebroeck, P | 1 |
| Laval, KU | 1 |
| van Cangh, P | 1 |
| Sánchez-Chapado, M | 2 |
| Guil, M | 2 |
| Alfaro, V | 2 |
| Badiella, L | 1 |
| Fernández-Hernando, N | 2 |
| Badiella, LI | 1 |
| Roehrborn, CG | 1 |
| Höfner, K | 1 |
| Jonas, U | 1 |
| Teillac, P | 1 |
| Cramer, P | 1 |
| Neveux, E | 1 |
| Régnier, F | 1 |
| Depassio, J | 1 |
| Bérard, E | 1 |
2 reviews available for alfuzosin and Urination Disorders
| Article | Year |
|---|---|
Alfuzosin for treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia: a systematic review of efficacy and adverse effects.
Topics: Adrenergic alpha-Antagonists; Humans; Male; Prostatic Hyperplasia; Quinazolines; Randomized Controll | 2005 |
Alfuzosin: a clinically uroselective alpha1-blocker.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Aged; Animals; Clinical Trials, Phase III as Top | 2002 |
19 trials available for alfuzosin and Urination Disorders
| Article | Year |
|---|---|
Effect of alfuzosin on female primary bladder neck obstruction.
Topics: Adrenergic alpha-Antagonists; Female; Humans; Middle Aged; Patient Satisfaction; Prospective Studies | 2009 |
Efficacy of alfuzosin and sildenafil combination in male patients with lower urinary tract symptoms.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Drug Therapy, Combination; Humans; Male; Middl | 2012 |
Comparative efficacy of two alpha-adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement.
Topics: Adrenergic alpha-Antagonists; Double-Blind Method; Doxazosin; Drug Administration Schedule; Humans; | 2004 |
Alfuzosin 10 mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunction.
Topics: Adrenergic alpha-Antagonists; Aged; Ejaculation; Humans; Male; Pain; Penile Erection; Quality of Lif | 2005 |
Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Double-Blin | 2005 |
Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction.
Topics: Adrenergic alpha-Antagonists; Aged; Drug Therapy, Combination; Erectile Dysfunction; Humans; Male; M | 2007 |
Alpha-blocking treatment with alfuzosin in symptomatic benign prostatic hyperplasia: comparative study with prazosin. The PRAZALF Group.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Double-Blind Method; Humans; Male; Middle Age | 1993 |
Validation of the self-administered Danish Prostatic Symptom Score (DAN-PSS-1) system for use in benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Humans; Male; Middle Aged; Prostatic H | 1995 |
Symptomatic outcome of transurethral prostatectomy, alpha-blockade and placebo in the treatment of benign prostatic hyperplasia. Evaluation of treatment with the Danish Prostatic Symptom Score (DAN-PSS-1) system. The ALFECH Study Group.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Follow-Up Studies; Humans; Male; Middle Aged; | 1996 |
[Role of alfuzosin in the treatment of functional voiding disorders in women].
Topics: Adolescent; Adult; Aged; Female; Humans; Middle Aged; Quinazolines; Urination Disorders | 1997 |
Comparison of the Danish Prostatic Symptom Score with the International Prostatic Symptom Score, the Madsen-Iversen and Boyarsky symptom indexes. ALFECH Study Group.
Topics: Adrenergic alpha-Antagonists; Double-Blind Method; Humans; Hyperthermia, Induced; Male; Microwaves; | 1998 |
Intermittent alpha-blocker therapy in the treatment of men with lower urinary tract symptoms.
Topics: Adrenergic alpha-Antagonists; Aged; Humans; Male; Middle Aged; Prospective Studies; Prostatic Hyperp | 1998 |
Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 12-18 month assessment. BPHALF Group.
Topics: Adrenergic alpha-Antagonists; Aged; Double-Blind Method; Humans; Male; Middle Aged; Prostatic Hyperp | 1993 |
Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study Group.
Topics: Adrenergic alpha-Antagonists; Aged; Delayed-Action Preparations; Double-Blind Method; Drug Administr | 2000 |
Safety and efficacy of sustained-release alfuzosin on lower urinary tract symptoms suggestive of benign prostatic hyperplasia in 3,095 Spanish patients evaluated during general practice.
Topics: Adrenergic alpha-Antagonists; Aged; Analysis of Variance; Blood Pressure Monitoring, Ambulatory; Del | 2000 |
The clinical uroselectivity of alfuzosin is not significantly affected by the age of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Adult; Age Factors; Aged; Humans; Male; Middle Aged; Prostatic Hyperpl | 2000 |
Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Antihypertensive Agents; Canada; Double-Blind | 2001 |
Urinary flow rates in patients with benign prostatic hypertrophy following treatment with alfuzosin. DUALF Group.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Double-Blin | 1992 |
[Efficacy of an alpha-blocker, alfuzosin, on urinary disorders in men with prostatic adenoma. Intermediate results of a European multicenter study].
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Europe; Huma | 1988 |
12 other studies available for alfuzosin and Urination Disorders
| Article | Year |
|---|---|
[Our experience with the use of alpha-lithic therapy in the treatment of voiding dysfunction].
Topics: Adrenergic alpha-1 Receptor Antagonists; Child; Child, Preschool; Doxazosin; Female; Humans; Male; Q | 2010 |
A current review of medical therapy for benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Algorithms; Azasteroids; Cholestenone 5 alpha-Reductase; Doxazosin; Dr | 2004 |
A comparison of four different alpha1-blockers in benign prostatic hyperplasia patients with and without diabetes.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Cohort Studies; Diabetes Mellitus; Doxazosin; | 2004 |
Symptom deterioration during treatment and history of AUR are the strongest predictors for AUR and BPH-related surgery in men with LUTS treated with alfuzosin 10 mg once daily.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Drug Administration Sch | 2005 |
Early symptom improvement of benign prostatic hyperplasia (BPH) treated with once daily alfuzosin.
Topics: Adrenergic alpha-Antagonists; Delayed-Action Preparations; Humans; Male; Middle Aged; Prostatic Hype | 2005 |
Alfuzosin 10 mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunction.
Topics: Adrenergic alpha-Antagonists; Aged; Dose-Response Relationship, Drug; Drug Administration Schedule; | 2005 |
Age, comorbidity and hypertensive co-medication do not affect cardiovascular tolerability of 10 mg alfuzosin once daily.
Topics: Adrenergic alpha-Antagonists; Age Factors; Aged; Antihypertensive Agents; Cardiovascular Diseases; D | 2006 |
Dynamic variables: novel and perhaps better predictors of progression in benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Disease Progression; Humans; Male; Prostatic Hyperplasia; Quinazolines | 2006 |
Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Aged; Drug Administration Schedule; Humans; Male; Middl | 2006 |
Lower urinary tract symptoms (LUTS) and sexual dysfunction (SD): new targets for new combination therapies?
Topics: Adrenergic alpha-Antagonists; Age Factors; Aged; Drug Therapy, Combination; Enzyme Inhibitors; Erect | 2007 |
Construction and validation of a short-form benign prostatic hypertrophy health-related quality-of-life questionnaire. BPH Group in General Practice.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Anxiety; Case-Control Studies; Cohort | 1997 |
Bladder-neck opening test in spinal cord injury patients using a new i.v. alpha-blocking agent, alfuzosin.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Female; Humans; Injections, Intravenous; Male | 1989 |